Cancer of Cervix Clinical Trial
Official title:
Efficacy of Percutaneous Electrical Neurostimulation (PENS)of the Auricle as an Opioid Sparing Postoperative Analgesic Technique in Cancer Endometrium and Cancer Cervix
NCT number | NCT05742711 |
Other study ID # | CS015 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 16, 2023 |
Est. completion date | November 2024 |
Pain relief following laparotomy surgery requires a variety of techniques including invasive ones like epidural or nerve blocks along with different classes of drugs, out of which opioids are most predominant. Each of these drugs have with their own set of advantages and also side effects. An ideal common system of analgesia is not possible due to patient variability. And no drug is devoid of side effects. Hence the aim is to ensure effective analgesia using drugs or techniques which are minimally invasive with negligible side effects.
Status | Recruiting |
Enrollment | 48 |
Est. completion date | November 2024 |
Est. primary completion date | November 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age >18 yrs - Diagnosed with CA-endometrium OR CA -cervix of stage I/II and post RT CA cervix patients coming for hysterectomy - Elective surgery - Informed consent obtained - ASA (American Society of Anaesthesiology) physical status 1-3 Exclusion Criteria: - Patient refusal - Cancer cervix other than the stages mentioned in inclusion criteria ASA PS >3 - Emergency surgery, Laparoscopic and robotic procedures - Unplanned postoperative ventilation - Allergy/sensitivity to adhesive - Active skin infection/lesion in the ear region - H/O of seizure or cerebral disease - H/O chronic pain and prolonged analgesic usage - H/O opioid dependence - H/O anxiety or psychiatric illness requiring treatment - Pre-existing implantable/ electronic on demand device - Patients who might require MRI in the study period - Patients with transmissible diseases - Patients with coagulopathies - Absolute or relative contraindication to drugs used in the study |
Country | Name | City | State |
---|---|---|---|
India | Cancer Institute,(Wia) | Chennai | Tamil Nadu |
Lead Sponsor | Collaborator |
---|---|
DyAnsys, Inc. |
India,
Arponrat P, Pongrojpaw D, Tanprasertkul C, Suwannarurk K, Bhamarapravatana K. Postoperative Pain Relief in Major Gynaecological Surgery by Perioperative Parecoxib Administration: Thammasat University Hospital Study. J Med Assoc Thai. 2015 Jul;98(7):636-42 — View Citation
Pogatzki-Zahn E, Kutschar P, Nestler N, Osterbrink J. A Prospective Multicentre Study to Improve Postoperative Pain: Identification of Potentialities and Problems. PLoS One. 2015 Nov 24;10(11):e0143508. doi: 10.1371/journal.pone.0143508. eCollection 2015. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Numeric Rating Scale (NRS) | The primary goal is to evaluate the efficacy of PENS treatment in the change in postoperative pain after cancer surgery compared to the control group. The pain is measured using the numerical rating scale (NRS). Pain Score will be measured on a scale (0 = no pain;10 = worst imaginable pain; lower scores indicate better outcome) | 0 - 4 days; 0 hours, 2 hours, 4 hours, 8 hours, 12 hours, 18 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours. Outcomes will be reported as an average over each individual postoperative day and as an average over 5 days independently for rest. | |
Secondary | Overall Postoperative analgesia and opioid requirement | To evaluate the effect of treatment in reducing the overall postoperative analgesia and opioid requirement. We will record the total dose and duration of additional analgesics required from the immediate postoperative period till pod 4 in iv morphine equivalents. | 0 - 4 days, duration and dose of all prescriptions are recorded. | |
Secondary | Patient Ambulation | Evaluate the ease of patient ambulation by assessing associated Numeric Rating Scale (NRS) score (0 = no pain;10 = worst imaginable pain; lower scores indicate better outcome) | 1 - 4 days; 24 hours, 36 hours, 48 hours, 72 hours, 96 hours. | |
Secondary | Record of Participant Bowel Movement Patterns | Onset of Bowel Movements - POD 1/POD 2/ POD 3/ > POD3 | 0 - 4 days; Whenever the patient experiences the bowel movement. | |
Secondary | Richmond Agitation Sedation Scale (RASS) | Compare Richmond Agitation Sedation Scale (RASS) score at a different time point during the follow-up time. RASS score will be measured on a scale (from -5 = Unarousable to +4 = Combative where 0 = Alert and calm) | 0 - 4 days; 0 hours, 2 hours, 4 hours, 8 hours, 12 hours, 18 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours. | |
Secondary | Patient Discomfort | Patient Discomfort due to device (Yes / no) | Time Frame: 0 - 4 days; Whenever the patient experiences the discomfort. | |
Secondary | Bleeding | Bleeding at the site of device placement (Yes / No) | Time Frame: 0 - 4 days; Whenever the patient experiences bleeding. | |
Secondary | Interference with Daily Activities | Interference with activities of daily living due to the device (Yes/No) | Time Frame: 0 - 4 days; Whenever the patient experiences disruption in daily activities. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03653819 -
High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs
|
N/A | |
Active, not recruiting |
NCT00193739 -
Neoadjuvant Chemotherapy Followed by Surgery Versus Concurrent Chemoradiation in Carcinoma of the Cervix
|
Phase 3 | |
Not yet recruiting |
NCT04999696 -
Minimally Invasive Therapy Versus Open Radical Hysterectomy for Management of Early Stage Cervical Cancer
|
N/A | |
Completed |
NCT02309658 -
Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients
|
Phase 2 | |
Completed |
NCT00193752 -
Para-Aortic Lymph Nodal Staging & Evaluation of Treatment Outcome by 18F FDG-PET in Advanced Cancer Cervix
|
N/A | |
Recruiting |
NCT00154479 -
The Correlation Between the Haplotype of Human Leukocyte Antigen (HLA) and Human Papillomavirus
|
N/A | |
Recruiting |
NCT05179824 -
Tempus Priority Study: A Pan-tumor Observational Study
|
||
Not yet recruiting |
NCT06147960 -
Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer
|
||
Completed |
NCT05149248 -
Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study
|
Phase 2/Phase 3 | |
Completed |
NCT00191100 -
Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix
|
Phase 3 | |
Completed |
NCT00193830 -
High Dose Rate (HDR) Versus Low Dose Rate (LDR) Brachytherapy in Carcinoma Cervix
|
Phase 3 | |
Completed |
NCT02865135 -
Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
Not yet recruiting |
NCT05824494 -
Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors
|
Phase 2 | |
Active, not recruiting |
NCT05709730 -
Follow-up of Cell Changes in the Cervix
|
||
Completed |
NCT00193791 -
Concomitant Chemoradiation in Advanced Stage Carcinoma Cervix
|
N/A | |
Withdrawn |
NCT02312804 -
Ph Ib/BGJ398/Cervix and Other Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03452774 -
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
|
||
Completed |
NCT00193804 -
A Trial Comparing Intensity Modulated Radiation Therapy (IMRT) With Conventional Radiation Therapy in Stage IIB Carcinoma Cervix
|
||
Completed |
NCT04809727 -
Histopathological Findings in Symptomatizing Patients After Supracervical Hysterectomy
|
N/A |